Precision Medicine for Liver Tumours With Quantitative Magnetic Resonance Imaging and Whole Genome Sequencing (Precision1)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04597710|
Recruitment Status : Active, not recruiting
First Posted : October 22, 2020
Last Update Posted : November 2, 2022
This will be a prospective, observational, cohort study to determine the impact of integrated diagnostics using quantitative magnetic resonance imaging, whole genome sequencing and digital pathology on intended patient management for liver cancer patients referred for liver resection.
Participants with primary or secondary liver cancer will be recruited from Hampshire Hospitals NHS Foundation Trust in Basingstoke or Oxford University Hospitals NHSFoundation Trust in Oxford. The incidence of treatable liver tumours is on the rise globally, driven by obesity, viral hepatitis and metastases from colorectal cancers. Survival rates can be improved with optimised allocation of treatment options including surgical resection, radiofrequency ablation, embolisation, chemotherapy and targeted molecular therapies (including immunotherapy).
The key motivation of this study is to help patients access the most suitable treatment combinations, based on integrating clinical, radiological and genomic data. A similar integrated approach, integrating radiology and pathology, has been shown to improve outcomes in breast cancer care. Detailed pathologic analysis of the surgical specimen from breast carcinoma biopsy provides valuable feedback to the radiologist, establishes the completeness of surgical intervention, and generates predictive information for therapeutic decisions. Whole genome sequencing (WGS) has discovered cancer driver mutations and the complex molecular profile of liver cancer. In many metastatic solid tumours, WGS has been used to identify a significant patient population (31%) who present with a biomarker that predicts sensitivity to a drug and lacked any known resistance biomarkers for the same drug. Identifying which patients possess druggable mutations will allow clinicians to make the optimal treatment decisions. The next challenge is integrating WGS into scalable clinical practice
|Condition or disease||Intervention/treatment|
|Liver Cancer Liver Metastasis Colon Cancer||Genetic: utility of whole genome sequencing (WGS) to aid clinical decision making in patients referred for liver resection|
|Study Type :||Observational|
|Estimated Enrollment :||200 participants|
|Official Title:||Precision Medicine for Liver Tumours With Quantitative Magnetic Resonance Imaging and Whole Genome Sequencing|
|Actual Study Start Date :||February 18, 2021|
|Estimated Primary Completion Date :||August 1, 2023|
|Estimated Study Completion Date :||August 1, 2023|
- Genetic: utility of whole genome sequencing (WGS) to aid clinical decision making in patients referred for liver resection
All participants will attend their planned outpatient surgery appointment.The consultant will document the intended treatment plan for each participant in line with their usual care pathway.Following this, participants will be required to attend three dedicated study visits:The results of the MRI scans from Study Visit 1 will be analysed into a LiverMultiScan report.A report will be sent to the consultant who will review their original documented care plan alongside the LiverMultiScan report.The consultant may update the intended care plan as a result of the LiverMultiScan report, in line with the device CE-marking.Any changes to the care plan will be documented.The patient will then undergo their planned treatment.The tumour explant will be collected and samples will be stored, transported and processed for genetic sequencing and digital histopathology.Study Visit 2 will be performed remotely 12 months following their planned treatment,where patient reported outcomes will be collected
- Proportion of patients for whom clinically-actionable data is provided by whole genome sequencing at the time of surgery. [ Time Frame: 36 months ]This will be evaluated retrospectively, with clinically-actionable data defined as data which would result in a clinician choosing a different medical intervention to the current standard of care.
- Proportion of patients for whom clinically-actionable data is provided by LiverMultiScan. [ Time Frame: 36 months ]. To determine the utility of quantitative multiparametric MRI with LiverMultiScan to aid clinical decision making in patients referred for liver resection.
- Correlation of computationally-derived digital pathology results with human pathologist assessments of the tumour and non-tumour tissue, along with assessment of intra- and inter-rater variability. [ Time Frame: 36 months ]To compare computationally-derived digital pathology results with human pathologist assessments of the tumour and non-tumour tissue.
- Correlation of MR measurements of steatosis and fibroinflammation with digital pathology and human pathology. [ Time Frame: 36 months ]To compare histopathological assessments of liver fat and fibroinflammation with quantitative MRI metrics (cT1, PDFF)
- Performance of WGS and LiverMultiScan for predicting post-surgery length of stay in hospital, post-operative liver function, 1-year mortality and recurrence rates. [ Time Frame: 36 months ]To evaluate the long term outcomes and recurrence rates and recurrence patterns of patients as it relates to imaging and whole genome sequencing.
- Proportion of patients for whom actionable biomarkers of drug sensitivity are identified with WGS. [ Time Frame: 36 months ]To evaluate whether whole genome sequencing enables better stratification of patients prior to surgery.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04597710
|Basingstoke and North Hampshire Hospital|
|Basingstoke, Hampshire, United Kingdom, RG249NA|
|Principal Investigator:||Rajarshi Banerjee||Perspectum Ltd|